# Phase 2 disease trials recruiting: 343 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 343 trials in phase 2 for disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 disease trials: 343 rows for $17.15, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 11 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 343
- Recruiting or not yet: 343
- Read on: November 19, 2026

## Trials

The 25 newest of 343, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07938021 | HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC) | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938021) |
| November 13, 2026 | NCT07935278 | Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain Injury | HealthPartners Institute | Phase 2 | Recruiting | Concussion (Diagnosis), Mild Traumatic Brain Injury | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935278) |
| November 12, 2026 | NCT07933328 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Alcohol-Associated Liver Disease, ALD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933328) |
| November 3, 2026 | NCT07914062 | PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates | Antev Ltd. | Phase 2 | Not yet recruiting | Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis), Dysmenorrhoea, Dyspareunia... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914062) |
| October 29, 2026 | NCT07905352 | A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease | Vigonvita Life Sciences | Phase 2 | Not yet recruiting | Alzheimer Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905352) |
| October 29, 2026 | NCT07904442 | Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis | Anhui Provincial Cancer Hospital | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904442) |
| October 29, 2026 | NCT07903038 | Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain Stimulation | Beijing Tiantan Hospital | Phase 2 | Not yet recruiting | Parkinson Disease (PD), Sleep Initiation and Maintenance Disorders, Deep Brain Stimulation | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903038) |
| October 27, 2026 | NCT07898709 | Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI | Al-Azhar University | Phase 2 | Not yet recruiting | No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898709) |
| October 22, 2026 | NCT07889245 | A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD. | Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. | Phase 2 | Not yet recruiting | sHTG, HTG With ASCVD (Diagnosed or at Increased Risk) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889245) |
| October 20, 2026 | NCT07883356 | Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) | Region Skane | Phase 2 | Not yet recruiting | Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy, Graves' Orbitopathy... | 554 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883356) |
| October 16, 2026 | NCT07878585 | Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | IgG4 Related Disease | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878585) |
| October 15, 2026 | NCT07875465 | Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic, Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875465) |
| October 14, 2026 | NCT07873463 | Flutemetamol F 18 Injection Formulation Comparison | GE Healthcare | Phase 2 | Recruiting | Cognitive Dysfunction | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873463) |
| October 13, 2026 | NCT07871669 | Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | Phase 2 | Not yet recruiting | Enteric Hyperoxaluria | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871669) |
| September 30, 2026 | NCT07850453 | Vortosiran for VTE Prevention | Ribocure Pharmaceuticals AB | Phase 2 | Not yet recruiting | Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850453) |
| September 24, 2026 | NCT07839936 | A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839936) |
| September 22, 2026 | NCT07832435 | A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures | Redx Pharma Ltd | Phase 2 | Not yet recruiting | Strictures Due to Crohn's Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832435) |
| September 22, 2026 | NCT07832383 | Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor | Neurocrine Biosciences | Phase 2 | Not yet recruiting | Alzheimer's Disease | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832383) |
| September 21, 2026 | NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | Novartis Pharmaceuticals | Phase 2 | Recruiting | Coronary Artery Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830719) |
| September 21, 2026 | NCT07830654 | This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of \[18F\]AV-133... | Michael J. Fox Foundation for Parkinson's Research | Phase 2 | Recruiting | Parkinson's Disease (PD), Healthy Control Subjects | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830654) |
| September 18, 2026 | NCT07827768 | AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease | Institute for Molecular Medicine | Phase 2 | Not yet recruiting | Preclinical Alzheimer's Disease, Alzheimer Disease | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827768) |
| September 15, 2026 | NCT07821320 | Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis | Medical University of Vienna | Phase 2 | Not yet recruiting | Endometriosis, Endometriosis (Diagnosis), Endometriosis and Dysmenorrhea, Endometriosis Associated Pelvic Pain | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821320) |
| September 8, 2026 | NCT07808112 | CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell... | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Graft -Versus-host-disease | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808112) |
| September 4, 2026 | NCT07804615 | A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently... | Vima Therapeutics | Phase 2 | Recruiting | PARKINSON DISEASE (Disorder) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804615) |
| September 4, 2026 | NCT07804381 | Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease | Yonsei University | Phase 2 | Not yet recruiting | Parkinson Disease | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804381) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 6 |
| M.D. Anderson Cancer Center | 6 |
| City of Hope Medical Center | 4 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| Peking Union Medical College Hospital | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3 |
| Mayo Clinic | 3 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 3 |
| Imperial College London | 3 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 3 |
| University of Minnesota | 3 |
| Yale University | 3 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 3 |
| New York Medical College | 3 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| University of Virginia | 3 |
| Sunnybrook Health Sciences Centre | 3 |
| University of California, Irvine | 2 |
| Ain Shams University | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| St. Petersburg State Pavlov Medical University | 2 |
| University of Colorado, Denver | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Fred Hutchinson Cancer Center | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 186 |
| China | 42 |
| Canada | 24 |
| United Kingdom | 24 |
| Spain | 23 |
| Poland | 22 |
| France | 21 |
| Australia | 21 |
| Germany | 21 |
| Italy | 20 |
| Taiwan | 14 |
| South Korea | 13 |
| Belgium | 11 |
| Hungary | 11 |
| Japan | 11 |
| Israel | 11 |
| Czechia | 10 |
| Netherlands | 10 |
| Brazil | 9 |
| Norway | 9 |
| Argentina | 8 |
| Russia | 8 |
| Romania | 7 |
| Slovakia | 7 |
| Bulgaria | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Taco restaurants in the United States](https://specstream.ai/data/businesses/taco-restaurants/united-states)
- [Hawaiian restaurants in the United States](https://specstream.ai/data/businesses/hawaiian-restaurants/united-states)
- [Advertising agencies in the United States](https://specstream.ai/data/businesses/advertising-agencies/united-states)
- [Locksmiths in the United States](https://specstream.ai/data/businesses/locksmiths/united-states)
- [Belgian restaurants in the United States](https://specstream.ai/data/businesses/belgian-restaurants/united-states)
